Table 3.
Change in Serum Biomarkers and Metabolic Factors From Baseline to Week 24
|
Selonsertib 18 mg ± Simtuzumab (n = 32) |
Selonsertib 6 mg ± Simtuzumab (n = 30) |
Simtuzumab (n = 10) | |
|---|---|---|---|
| Enhanced Liver Fibrosis test | 0.02 (–0.34 to 0.52) | –0.07 (–0.46 to 0.36) | –0.13 (–0.35 to 0.05) |
| FibroSure/FibroTest | –0.01 (–0.03 to 0.03) | 0.02 (–0.03 to 0.08) | 0.01 (–0.04 to 0.05) |
| ALT, U/L | –8 (–24 to 23) | –6 (–29 to 7) | –3 (–16 to –1) |
| AST, U/L | –5 (–13 to 13) | –4 (–25 to 17) | –3 (–28 to –1) |
| Gamma‐glutamyltransferase, U/L | –7 (–19 to 5) | –2 (–15 to 11) | –2 (–9 to 2) |
| Triglycerides, mg/dL | –21 (–41 to 29) | 12 (–6 to 32) | –30 (–9 to 28) |
| Total cholesterol, mg/dL | –10 (–33 to 8) | –5 (–24 to 14) | –13 (–36 to 2) |
| High‐density lipoprotein, mg/dL | –2 (–3 to 1) | 1 (–5 to 5) | 2 (–4 to 5) |
| Low‐density lipoprotein, mg/dL | –10 (–24 to 6) | –5 (–19 to 9) | –25 (–31 to 0) |
| HOMA‐IR | 0.98 (–2.4 to 7.63) | 2.17 (0.16‐4.77) | –0.22 (–1.90 to 0.12) |
| Hemoglobin A1c, % | –0.2 (–0.5 to 0.2) | 0.2 (0.0‐0.5) | –0.2 (–1.1 to 0.6) |
| CK‐18 fractions | |||
| M30, U/L | –110 (–338 to 124) | –34 (–445 to 241) | –89 (–378 to 146) |
| M65, U/L | –222 (–811 to 238) | –162 (–820 to 341) | –185 (–820 to 251) |
Values are median (interquartile range)
Abbreviations: CK, cytokeratin; HOMA‐IR, homeostatic model assessment for insulin resistance.